AI Article Synopsis
- Cardiac involvement is a key factor in predicting outcomes for patients with primary amyloidosis (AL), as it can lead to various heart-related issues like heart failure and arrhythmias.
- A case study of a 70-year-old woman highlights the complexities of managing amyloid cardiomyopathy, as conventional heart failure medications are often not suitable.
- The patient presented with severe symptoms, including syncope and a need for a pacemaker, and was diagnosed with amyloidosis after a biopsy, ultimately passing away from end-stage heart failure.
Article Abstract
Cardiac involvement is the most important prognostic factor in primary amyloidosis (AL). The clinical presentation of amyloid cardiomyopathy is varied and may manifest as heart failure, brady or tachyarrhythmias, syncope, angina and rarely with features of hypertrophic cardiomyopathy and advanced symptomatic conduction system disease. The management of amyloid cardiomyopathy has always been a dilemma, as most of the drugs used in congestive heart failure are contraindicated. This report describes a 70-year-old woman who presented with syncope, severe diastolic heart failure, features of hypertrophic cardiomyopathy and severe symptomatic conduction system disease requiring a pacemaker. Amyloidosis was diagnosed on endomyocardial biopsy after abdominal fat aspirate was negative for amyloid. The patient eventually expired due to end-stage congestive heart failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.smj.0000251327.38080.f1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!